Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials
| Autor: | María-Asunción Echeveste, Anna Sureda, María-Belén Vidriales, María-Angeles Montalbán, Albert Oriol, Luis Palomera, Adrian Alegre, Lourdes Cordón, Felipe de Arriba, Bruno Paiva, Juan José Lahuerta, Norma C. Gutiérrez, Alberto Orfao, Ana Gorosquieta, José J. Pérez, Joan Bladé, Joaquín Díaz-Mediavilla, Raquel de Paz, Joaquin Martinez-Lopez, Alejandro Martín, Javier de la Rubia, María-José Terol, Maria-Victoria Mateos, Jesús F. San Miguel, Laura Rosiñol |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Oncology
Melphalan Vincristine Pathology medicine.medical_specialty Cyclophosphamide Proliferation index Plasma Cells Antineoplastic Agents Disease-Free Survival Pathology and Forensic Medicine Autologous stem-cell transplantation Internal medicine medicine Humans Multiple myeloma Aged Cell Proliferation Carmustine Dose-Response Relationship Drug business.industry DNA Neoplasm Middle Aged Flow Cytometry medicine.disease Clone Cells medicine.anatomical_structure Spain Multivariate Analysis Bone marrow Multiple Myeloma business Stem Cell Transplantation medicine.drug |
| Zdroj: | AMERICAN JOURNAL OF PATHOLOGY r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe instname |
| ISSN: | 0002-9440 |
| DOI: | 10.1016/j.ajpath.2012.07.020 |
| Popis: | The incorporation of high-dose therapy/autologous stem cell transplantation (HDT/ASCT) and novel agents has significantly improved survival in patients with multiple myeloma (MM), but whether this improvement also benefits patients harboring poor prognostic features, such as nonhyperdiploid MM (NH-MM) and a high proliferation index, remains largely unknown. We analyzed the DNA content and proliferation index of bone marrow plasma cells (PCs) by multiparameter flow cytometry in 595 newly diagnosed transplant-eligible patients with MM included in two consecutive PETHEMA/GEM trials: GEM2000 [VBMCP/VBAD (vincristine, carmustine, melphalan, cyclophosphamide, prednisone/vincristine, bischloroethylnitrosourea, adriamycin, and dexamethasone) followed by HDT/ASCT; n = 319] and GEM2005 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|